Which eye drop heals your cornea faster after laser surgery?
NCT ID NCT04704518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two eye drops, Lagricel and Thealoz, to see which helps the cornea heal faster after PRK laser eye surgery. 96 adults who had PRK surgery used one of the drops four times a day for two weeks. The main goal was to measure how quickly the cornea's outer layer closed up after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
96 people
The number who actually took part.
- Started
-
Sep 2022
- Finished
-
Dec 2023
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * \- Age ≥ 18 and ≤ 45 years old * Being on PRK postoperative day 1 (right eye will be evaluated for efficacy) * Presenting a PRK surgical corneal ablation surface of 5.5 to 6.0 mm * PRK corneal output ≤ 60 µm * Preoperative refraction of -1.0 to -4.5 D of myopia or myopic astigmatism (in this case, the sum of both values with a spherical equivalent no greater than -4.5 D) * Being capable of voluntarily grant a signed informed consent. * Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures. * Being willing and able to modify the required lifestyle activities. * Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal contraceptive method or intrauterine device (IUD) during the study. Exclusion Criteria: * Having suffered any complications during and after PRK surgical procedure previous to inclusion in the study. * Use of mitomycin during PRK * Being subjected to PRK retreatment of previous history of any other kind of refractive surgery. * Pregnancy, breastfeeding or planning to become pregnant during the time of the study * Having participated in clinical trials within 30 days prior to signing this study's informed consent form. * Having participated previously in this study. * Diagnosis of any of the following: * Allergic, viral or bacterial conjunctivitis * Dry eye * Anterior blepharitis * Parasite infestation of ocular structures (Demodex, for example) * Previous history of ocular herpes * Previous history of ocular inflammation (such as uveitis) * Corneal or conjunctival ulcers * Glaucoma * Previous history of drug addiction within the last 2 years previous to signing this study's informed consent form. * Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date. * Previous history of any medical affliction, acute or chronic (such as Diabetes Mellitus type I/II, autoimmune diseases or HIV), that according to the investigator may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results. * Use of medications (such as retinoic acid) that according to the investigator's criteria may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results. * Known hypersensitivity to any of the components of the products used in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Corneal de-epithelialization are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aris Vision Institute de Guadalajara, S. C.
Guadalajara, Jalisco, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.